Table 2.
Incidence rates (IR) and subhazard ratios (sHR) for outcomes in relation to OAC treatment
| As treated during follow-upa |
As treated at baselineb |
||||||
|---|---|---|---|---|---|---|---|
| Events | IR per 100 risk years (95% CI) | sHR (95% CI) | Events | IR per 100 risk years (95% CI) | sHR (95% CI) | ||
| Composite brain endpoint | No OAC | 535 | 0.84 (0.77–0.92) | Reference | 1279 | 1.14 (1.08–1.20) | Reference |
| OAC | 380 | 0.72 (0.81–0.92) | 0.88 (0.77–1.00) | 938 | 0.86 (0.81–0.92) | 0.77 (0.70–0.83) | |
| Dementia | No OAC | 174 | 0.27 (0.23–0.31) | Reference | 288 | 0.25 (0.22–0.28) | Reference |
| OAC | 88 | 0.16 (0.13–0.20) | 0.62 (0.48–0.81) | 215 | 0.19 (0.17–0.22) | 0.79 (0.66–0.94) | |
| Ischaemic stroke | No OAC | 331 | 0.52 (0.46–0.58) | Reference | 955 | 0.84 (0.79–0.90) | Reference |
| OAC | 246 | 0.46 (0.41–0.53) | 0.92 (0.78–1.09) | 618 | 0.56 (0.52–0.61) | 0.68 (0.61–0.75) | |
| ICH | No OAC | 63 | 0.10 (0.08–0.12) | Reference | 116 | 0.10 (0.08–0.12) | Reference |
| OAC | 60 | 0.11 (0.09–0.14) | 1.19 (0.84–1.70) | 148 | 0.13 (0.11–0.16) | 1.35 (1.06–1.72) | |
| Death from any cause | No OAC | 1461 | 2.25 (2.14–2.37) | Reference | 1885 | 1.63 (1.56–1.70) | Reference |
| OAC | 659 | 1.23 (1.14–1.33) | 0.54 (0.50–0.60) | 1465 | 1.32 (1.25–1.39) | 0.81 (0.75–0.87) | |
| Falsification endpointc | No OAC | 2652 | 4.61 (4.44–4.79) | Reference | 5084 | 5.05 (4.92–5.20) | Reference |
| OAC | 2381 | 5.14 (4.94–5.35) | 1.14 (1.08–1.20) | 4964 | 5.19 (5.04–5.33) | 1.03 (1.00–1.08) | |
a
Comparison of outcomes for 17 092 patients never exposed to OAC and 20 329 patients who used OAC >80% of time at risk, all within the propensity-score matched cohorts.
b
Comparison of outcomes for patients propensity score matched for the likelihood of OAC treatment at baseline, with 23 746 patients in each group.
c
Composite endpoint consisting of fall accident, pneumonia, newly diagnosed osteoarthritis, newly diagnosed diabetes, and newly diagnosed chronic obstructive pulmonary disease.